Sequential metastasis-directed therapy in renal-cell carcinoma: promising, but unproven without randomised evidence
Mené sur 121 patients atteints d'un carcinome rénal à cellules claires oligométastatique (durée médiane de suivi : 36,3 mois), cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, d'un traitement ciblant les métastases et retardant le recours à une thérapie systémique
The advent of metastasis-directed therapy has reshaped treatment strategies across various solid tumours, including renal-cell carcinoma.1,2 Once deemed to be radioresistant, renal-cell carcinoma can now be effectively treated in select patients using stereotactic ablative radiotherapy.3,4 In this context, the phase 2 trial by Chad Tang and colleagues, published in The Lancet Oncology,5 adds to the growing evidence for sequential metastasis-directed therapy in patients with systemic therapy-naive oligometastatic clear-cell renal-cell carcinoma—a strategy first reported in 2019 and explored prospectively since 2016.
The Lancet Oncology , commentaire, 2025